Leadership Team

Walter Ferlin, CSO

Born in Australia, Walter went on to obtain his PhD in Immunology at the University of California, Davis and the DNAX Research Institute in Palo Alto, California.

In 2003, Walter joined Novimmune as the leader of the anti-interferon gamma antibody program (NI-0501) which in 2018 became Novimmune’s first approved drug and the first and only treatment for primary Hemophagocytic lymphohistiocytosis.

Walter has led the preclinical and translational sciences team for the development of monoclonal antibodies and, more recently, bispecific antibodies in the field of immuno-oncology.